Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma

Study Overview
=================
Brief Summary
-----------------
This study looks at the efficacy of Doxycycline for the treatment of Cutaneous T-cell Lymphomas.

Detailed Description
-----------------
The aim of this study is to evaluate the efficacy of doxycycline in relapsed Cutaneous T-cell Lymphomas (CTCL). The primary objective is to determine the overall response rate of doxycycline monotherapy in patients with relapsed CTCL.

Official Title
-----------------
Doxycycline in Patients With Relapsed Cutaneous T-cell Lymphoma

Conditions
-----------------
Cutaneous T-cell Lymphoma, Mycosis Fungoides, Sezary Syndrome

Intervention / Treatment
-----------------
* Drug: Doxycycline monohydrate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Voluntarily signed and dated Institutional Review Board approved informed consent form in accordance with regulatory and institutional guidelines. Written informed consent must be obtained prior to performing any study-related procedure. Be 18 years of age or older at time of enrollment. Measurable disease in at least one target lesion in the skin or able to be assessed by radiographic examination with FDG-PET fluorodeoxyglucose possitron emission tomography (FDG-PET) scan or computarized tomography (CT) scan, or peripheral blood showing involvement of lymphoma. The subject has resolution of all clinically significant toxic effects of prior cancer therapy to Grade ≤1 by the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0 (NCI-CTCAE, v.4.0) excluding the specification below. Adequate organ function: Absolute Neutrophil Count (ANC) > 500 cells/mL and platelet count > 50,000 cells/mL unless felt to be secondary to lymphoma at which any count is permissible. Adequate renal function as determined by creatinine < 1.5x upper limit normal (ULN) or estimated creatinine clearance of ≥ 60ml/min Adequate hepatic function as determined by total bilirubin < 1.5x ULN (unless known Gilbert syndrome), Alanine transaminase (ALT) and Aspartate transaminase (AST) < 2.5x ULN Confirmed diagnosis of CTCL. Karnofsky Performance Status ≥ 60% Women of childbearing potential (WOCBP) must have a negative pregnancy test within 7 days of receiving study medication and monthly while on receiving doxycycline WOCBP must agree to use effective contraception, defined as, oral contraceptives, double barrier method (condom plus spermicide or diaphragm plus spermicide) or practice true abstinence from sexual intercourse (periodic abstinence, e.g., calendar ovulation, symptothermal, post-ovulation methods and withdrawal are not acceptable methods of contraception) during the study and for 3 months after the last dose. WOCBP includes any female who has experienced menarche and who has not undergone successful surgical sterilization or is not postmenopausal (defined as amenorrhea ≥ 12 consecutive months without an alternative medical cause). Male subjects and their female partners of child bearing potential must be willing to use an appropriate method of contraception defined as, oral contraceptives, double barrier method (condom plus spermicide or diaphragm plus spermicide) or practice true abstinence from sexual intercourse (periodic abstinence, e.g., calendar, ovulation, symptothermal, post-ovulation methods and withdrawal are not acceptable methods of contraception) during the study and for 3 months after the last dose. Exclusion Criteria: Known sensitivity or allergy to tetracyclines Lack of measurable disease Karnofsky Performance Status <60% Inadequate organ function as measured by not fulfilling above criteria Subject is pregnant or breast-feeding.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Doxycycline monohydrate<br>Doxycycline in either capsules or tablets will be administered at 400mg total per day. Patients will be treated for five months, or up to one year for those with a partial response at 5 months. | Drug: Doxycycline monohydrate<br>* Doxycycline will be administered in either tablets or capsules for either five months or a year depending on response.<br>* Other names: Adoxa, Mondox;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy of Doxycycline in relapsed CTCL | Overall response rate will be determined after five months or a year from initiation of therapy. | From baseline to five month or a year depending on response. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Duration of Response | Patients who achieve a Partial Response or Complete Response will be monitored for progression up to one year after initiation of therapy. | From baseline to up to one year. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
CTCL, Sezary Syndrome (SS), Mycosis Fungoides (MF), Cutaneous T-cell Lymphoma, MF, SS